AC ImmuneACIU
Market Cap: $296M
About: AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
Employees: 161
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
419% more call options, than puts
Call options by funds: $1.14M | Put options by funds: $219K
133% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 6
27% more capital invested
Capital invested by funds: $89.8M [Q1] → $114M (+$24.2M) [Q2]
22% more funds holding
Funds holding: 37 [Q1] → 45 (+8) [Q2]
1.79% less ownership
Funds ownership: 30.59% [Q1] → 28.8% (-1.79%) [Q2]
50% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 16
Research analyst outlook
We haven’t received any recent analyst ratings for ACIU.